78 results about "Downregulated gene" patented technology

Disclosed is a method of down-regulating the expression of a gene in an animal, wherein a pharmacological formulation comprising a chimeric oligonucleotide complementary to the gene is orally administered to an animal. The oligonucleotide administered has at least one phosphorothioate internucleotide linkage and at least one alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, phosphoramidite, phosphate ester, carbamate, carbonate, phosphate triester, acetamidate, or carboxymethyl ester internucleotide linkage.

In the present invention, the markers identified for liver fibrosis and cirrhosis and the microarray panel thereof comprise at least one of the following proteins/genes:

8 up-regulated genes such as

ANXA2; COL1A2; COL3A1; GSN; LDHB; LUM; PDGFRA and TIMP1.

13 down-regulated genes such as

ALB; ANPEP; APOF; AZGP1; BHMT C8A; CFHR4; CFHR5; COL18A1; FTCD; GYS2; ITIH1, and THRAP1.

9 therapeutic targets such as PDGFRA; S100A4; COL3A1; CCL19; DCN; DPT; APP; TNF; and INFG.

The present invention is capable of screening markers for the early warning of the occurrence for severe fibrosis or cirrhosis and potentially targets for drug design.

Recombinant nucleic acid molecules are provided that form hair pin structures and can be used to down-regulate gene expression. For example, a nucleic acid molecule can comprise a flanking and lower stem loop sequence from a mir-16 gene; an antisense target sequence; a mir-30 loop sequence; a complement of the anti-sense target sequence; and a lower stem loop complementary to the mir-16 sequence. Methods for down regulating gene expression in a cell using such recombinant nucleic acid molecules are also provided.

Phamaceutical compositions are provided that are useful in treating amyloid protein-related diseases such as Alzheimer's disease. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that downregulates one or more genes related to the amyloid-related disease. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of amyloid protein-related diseases. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl), and the amyloid protein-related disease is Alzheimer's disease. In a preferred embodiment, the downregulated genes are genes related to inflammation or oxidative stress.

The invention relates to the effect of miR-451a cells in the non-small cell lung cancer. Migration of A549 cells can be significantly inhibited through overexpression of miR-451a in the A549 cells. By means of the bioinformatics analysis means, it is predicted that translation of the target gene mRNA is inhibited or the target gene mRNA is directly degraded by miR-451a through regional complementation with 3'-UTR of the target gene CAB39 mRNA; it is determined that the CAB39 gene is the target gene of miR-451a through double-luciferase reporter gene system analysis and Western Blot experiment verification. Finally, it is verified through the Transwell Assay and Flow Cytometry Assay experimental means that miR-451a performs the function of inhibiting migration of cells by reducing the CAB39 gene in the A549 cells, and a novel accurate treating researching and treating scheme is provided. By means of the effect, important research guidance and application value is provided for using miRNA for diagnosing and treating the non-small cell lung cancer and searching for drug targets in the fields such as tumor immunotherapy clinically.

The invention discloses an application of noble dendrobium total alkali in preparing a drug for atherosclerosis and belongs to the technical field of biomedicine. According to the application of nobledendrobium total alkali in preparing the drug for atherosclerosis, the noble dendrobium is biennial noble dendrobium and the dosage of the noble dendrobium total alkali is 20-180 mg/kg per day. The invention further explicits the degreasing action of noble dendrobium total alkali DNLA and a probable action mechanism thereof. By adopting an experimental rat atherosclerosis model and an ApoE-/- mouse transgenic model, influence of the DNLA on hyperlipidemia atherosclerosis of blood vessels is observed, and the action mechanism thereof is analyzed, finding that the DNLA has preventing and treating action on the rat atherosclerosis model and the action mechanism is partially related to down-regulation of expression of MCP-1/CCR2, MCPIP and CRP genes, thereby providing a basic pharmacologicalbasis for clinical treatment of HLP and As by DENLA.

The invention discloses an SiRNA inhibiting the gene expression of a buffalo growth differentiation factor GDF9, and belongs to the technical field of gene engineering. The positive-sense strand of the siRNA has any sequence indicated by SEQ ID NO: 1-3. The invention also discloses an shRNA encoding gene containing the siRNA and slow virus interference plasmid pshRNA-copGFPLentivector constructed by the same. Through real-time quantitative Real-time PCR (Polymerase Chain Reaction) detection, a relative expression quantity is calculated according to a formula, wherein the buffalo GDF9 mRNA inhibiting efficiencies of two siRNA segments respectively exceed 100%, and the CDF9 protein expression quantity detected by the ELISA (enzyme-linked immuno sorbent assay) is also correspondingly reduced. The siRNA segments and the expression vector thereof can be used to prepare a preparation inhibiting the expression of buffalo GDF9, and can significantly reduce the GDF9 gene expression quantity.

The invention discloses application of a GPR115 gene in preparation of an anti-lung cancer drug and a diagnostic kit thereof, and belongs to the technical field of cancer precision medical drugs. Immunohistochemistry proves that the expression of GPR115 in lung cancer is increased through a lung cancer clinical sample tissue chip, and GPR115 is related to prognosis; the influence of down-regulation of GPR115 gene expression by siRNA on biological behaviors such as proliferation and invasion of lung cancer cells is studied through an in-vitro cell experiment, it is found that the specific siRNAsequence can effectively inhibit the expression of GPR115 protein in human lung cancer cell strains H1650 and SPCA, and after the expression of GPR115 is inhibited by siRNA, the proliferation of H1650 and SPCA cells is slowed down, and the cell invasion ability is reduced. The GPR115, as a target for lung cancer gene therapy, can be widely applied to preparation of a diagnostic kit for precisionmedical treatment and treatment of lung cancer with high expression of GPR115.

The invention relates to methods of regulating gene expression, e.g., to turn on or off, or up or down gene expression in an organism when and where desired, without the toxic side effects usually associated with other contemporary methods, such as those toxic side effects caused by introducing compounds that do not naturally occur in life.

The invention discloses a method for increasing saccharification efficiency of plants by down-regulating a UXT (UDP-Xylose transporter) gene and an application of the method and belongs to the field of biomass energy. According to the method, the saccharification efficiency of the plants is increased by eliminating functions of the UXT gene or down-regulating the UXT gene. By means of the method, xylose content is reduced, relative cellulose content is increased correspondingly, by means of xylose content reduction, the saccharification efficiency of a mutant material is increased and the material disposal cost is reduced. Therefore, biomass characteristics of the material are changed fundamentally, the saccharification efficiency is increased radically, energy can be saved, and labor intensity can be reduced. The material obtained with the method can be applied to biomass transformation, pulp and papermaking industries.

The present invention provides polymeric siRNA conjugates. Methods for down-regulation of gene expression in vivo and in vitro and for inhibition of the growth of cancer cells using the conjugates are also disclosed.

The invention belongs to the technical field of biological information determination, and discloses a biological information determination method and system, a storage medium, and a terminal. The method comprises the following steps: screening of differentially-expressed genes of pancreatic cancer; GO analysis of the differentially-expressed genes of pancreatic cancer: respectively carrying out GOannotation and graphical display on the obtained differentially-expressed up-regulation and down-regulation genes; KEGG analysis of the differentially-expressed genes of pancreatic cancer: respectively carrying out pathway enrichment and network diagram display on the differentially-expressed up-regulation and down-regulation genes; and PPI interaction network analysis of the differentially-expressed genes and core genes of pancreatic cancer to determine a signal transduction pathway of the differentially-expressed genes. According to the invention, a bioinformatics means is adopted to screenthe differentially-expressed genes of pancreatic cancer and a signal transduction pathway of the differentially-expressed genes, and a molecular mechanism of the occurrence and development of pancreatic cancer is disclosed, so a theoretical basis is provided for early diagnosis and prevention of pancreatic cancer, and an effective target is provided for treatment of pancreatic cancer.

The invention discloses a lung adenocarcinoma related diagnostic marker and an application thereof. The diagnostic marker is used for encoding IL1F5 protein and encoding mRNA of the IL1F5 protein. PCRdetection and tissue chip immunohistochemistry of a clinical lung adenocarcinoma sample prove that the expression of IL1F5 in the lung adenocarcinoma is increased, and survival analysis shows that the prognosis of a patient with higher expression of the IL1F5 is poorer. Influence of down-regulation of the IL1F5 gene expression by siRNA on biological behaviors such as lung adenocarcinoma cell proliferation and invasion is studied through in-vitro cell experiments, and it is found that a specific siRNA sequence can effectively inhibit expression of the IL1F5 protein in a human lung adenocarcinoma cell strain H1299. Under the condition of co-cultivation with CD8+T cells, the proliferation and invasion capacities of H1299 cells with reduced IL1F5 expression are reduced (no difference exists when the tumor cells are cultured alone).

The invention belongs to the biomedical field and relates to a construction method of a shRNA (short hairpin RNA, shRNA) recombinant adeno-associated virus vector for specially restraining SOCS1 gene expression and an application of the construction method. The shRNA recombinant adeno-associated virus vector is transferred to a monocyte-macrophage-dendritic cell system for lowering the SOCS1 gene expression and strengthening the anti-tumor activity of CTL (Cytotoxic T Lymphocyte). Therefore, the construction method can play an important role in the biomedical field and the research of gene function, can be used for preparing anti-tumor dugs and is high in clinical application value.

The invention provides an application of a DCUN1D1 gene to control of vitiligo. Through research, the applicant finds that the DCUN1D1 gene expression of a patient suffering from vitiligo is increased, and experimentation on animals confirms that specific overpression of DCUN1D1 on keratinocyte can enable local facial depigmentation of mice, growth of hair follicles is restrained, the skin thickness is thinned, and chromogenesis in the hair follicles is restrained. The DCUN1D1 gene is promoted to be a new target point of medicines for treating vitiligo, the expression of the DCUN1D1 gene is reduced to promote proliferation of the keratinocyte, reduce apoptosis and promote melanocyte migration, and the application is a new way of treatment with medicines. The application has the beneficialeffects that the new gene target point for treatment of vitiligo is found, a new purpose of a DCUN1D1 gene inhibitor to preparation of medicines for treating facial depigmentation particularly medicines for treatment of vitiligo is provided, and a foundation is provided for screening of new medicines.

The invention discloses application of SFN (sulforaphane) to preparation of medicine for treating leukemia, and belongs to the technical field of novel purpose of the SFN. The application is characterized in that according to the application of the SFN to the preparation of the medicine for treating the leukemia, the SFN promotes the leukemia apoptosis through raising Bax genes and Caspase-3 genes and reducing Bcl-2 genes for further inhibiting the multiplication of leukemia cells. The influence of the SFN on the acute leukemia cell KG1a and K562 apoptosis is systematically discussed for the first time; a result proves that the SFN can promote the acute leukemia apoptosis through regulating and controlling the Bax genes, the Bcl-2 genes and the Caspase-3 genes; the result belongs to the theoretical breakthrough and has the potential clinic application significance; a fire-new thought and potential treatment path is provided for leukemia treatment.

The invention discloses a siRNA for inhibiting expression of a porcine Somatostatin receptor 2, belonging to the technical field of genetic engineering. The siRNA sense strand provided by the invention has any sequence shown in the SEQID NO:1-3. The invention further discloses shRNA coding genes containing the siRNA and lentivirus interfering plasmids pshRNA-copGFPLentivector constructed with theshRNA coding genes. Through the real-time quantitative Real-time PCR (Polymerase Chain Reaction) examination, it is found that the expression level of a porcine Somatostatin receptor 2mRNA can be remarkably reduced by about 70% above with each siRNA segment and the expression level of SSTR 2 proteins can be reduced by 30% above in ELISA (Enzyme Linked Immunosorbent Assay) examination. The siRNA segment provided by the invention and expression vectors thereof can be used for preparing preparations of inhibiting the porcine Somatostatin receptors 2 and can be used for remarkably reducing the expression level of the SSTR2 (porcine Somatostatin Receptor 2) genes.

The invention provides a preparation method of renal cell carcinoma tumor antigen CA9 specific cytotoxic T lymphocytes, which comprises the following steps: infecting mature DC cells with a recombinant vector containing siRNA targeting SOCS1 and carbonic anhydrase 9 to obtain iSOCS1-CA9-DC cells; and then carrying out mixed culture on the iSOCS1-CA9-DC cells and T cells to obtain CA9-DC-CTL cells,namely the cytotoxic T lymphocytes with antigen specificity. According to the invention, replication-defective adenovirus mediated RNAi is adopted to down-regulate SOCS1 gene expression, and CA9 andS-Flagellin are combined to stimulate DC cell maturation so as to induce specific CTL to resist renal cell carcinoma. The targeting property of CTL to kidney cancer cells is effectively enhanced, damage to autologous cells is avoided, growth of tumors can be effectively inhibited, and the lifetime of a patient is prolonged.

The invention relates to a novel pharmaceutical application of apatinib or a pharmaceutically acceptable salt thereof, in particular to an application of apatinib or a pharmaceutically acceptable saltthereof in preparation of a medicine for treating malignant mesothelioma. The in-vitro test result shows that apatinib mesylate inhibits MPM cell proliferation and activity, affects the G2/M phase ofthe MPM cell cycle process and remarkably inhibits MPM cell movement and migration; an in-vivo test result shows that the apatinib mesylate obviously reduces the ePCI score and has no influence on the body weight of nude mice. The apatinib has no histological toxicity to lung, spleen, kidney and gastrointestinal tract, only has focal lymphocyte infiltration in liver and myocardial tissues, and has an obvious effect of down-regulating NPM2 gene expression. The new application of apatinib or the pharmaceutically acceptable salt thereof provided by the invention provides an important theoreticalbasis for application of apatinib or the pharmaceutically acceptable salt thereof in treatment of malignant mesothelioma, widens the treatment range of the drug, and provides a new drug solution fortreatment of malignant mesothelioma.